Search

Your search keyword '"Baden, Lindsey R"' showing total 1,572 results

Search Constraints

Start Over You searched for: Author "Baden, Lindsey R" Remove constraint Author: "Baden, Lindsey R"
1,572 results on '"Baden, Lindsey R"'

Search Results

1. IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition

2. Risk of COVID-19 after natural infection or vaccination

3. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

4. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

6. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

7. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study

8. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

9. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients

10. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

12. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

13. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial

14. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

15. Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series

16. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

17. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

18. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans

20. Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice

21. Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice

22. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

23. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study

24. The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo

26. Risk of COVID-19 after natural infection or vaccination

27. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

28. Immunogenicity of quadrivalent meningococcal conjugate vaccine in frequent platelet donors

30. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients

31. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies

32. Diagnostic TR-FRET assays for detection of antibodies in patient samples

34. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies

38. Disseminated Mycobacterium avium Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma.

39. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines.

40. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.

43. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

45. COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials

46. A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals

47. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines

49. Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

Catalog

Books, media, physical & digital resources